Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We agree with the points Drs Luo and Kesselheim raised and have the following points to add regarding our cost-effectiveness analysis in light of these issues.
As Luo and Kesselheim noted, we used the weighted average of the lowest Red Book wholesale acquisition costs in our base-case analysis, but also paid particular attention to the price of statins when presenting our results. Specifically, we presented (1) separate cost-effectiveness analysis tables for blended generic/branded and generic-only drug prices and (2) a 1-way sensitivity analysis figure showing the optimal ASCVD treatment threshold as a function of drug cost for 3 separate cost-effectiveness thresholds ($50 000/QALY, $100 000/QALY, and $150 000/QALY).
Pandya A, Weinstein MC, Gaziano TA. Cost-effectiveness of Statin Therapy for ASCVD—Reply. JAMA. 2015;314(20):2191–2192. doi:10.1001/jama.2015.12928
Customize your JAMA Network experience by selecting one or more topics from the list below.